Key facts
- This page summarizes John C. Thomas's Form 4 filing for Virios Therapeutics, Inc. (DWTX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 28 Feb 2024, 13:09.
John C. Thomas - 26 Feb 2024 Form 4 Insider Report for Virios Therapeutics, Inc. (DWTX)
- Reporting relationship
- Director
- Issuer ticker
- DWTX
- Reported as of
- 26 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Feb 2024, 13:09:44 UTC
- Prior SEC filing
- 20 Jun 2023
- Next SEC filing
- 23 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Greg Duncan, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John C. Thomas filed Form 4 for Virios Therapeutics, Inc. (DWTX) on 28 Feb 2024.
Change
- Previous filing in this sequence was filed on 20 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VIRI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +4,167
- Change %
- Price
- $0.000000
- Shares after
- 4,167
- Date
- 26 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,167
- Exercise price
- $0.3570
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option will vest 100% on February 26, 2025, one year following the grant date.